TheraRadar
← Back
Data updated: Mar 29, 2026

UCB INC

NeurologyImmunology
Specialty

UCB INC is a specialty pharmaceutical company focused on Neurology, Immunology. Key products include FINTEPLA.

1955
Since
34
Drugs
-
Trials
171
Approved (2yr)

Key Drugs

FINTEPLA
fenfluramine hydrochloride
5-HT2 receptor 3 indications · 2020
NAYZILAM
midazolam
CNS
GABA A receptor 2 indications · 2019
BRIVIACT
brivaracetam
SV2A 1 indications · 2016
KYGEVVI
doxecitine
1 indications · 2025
ZILBRYSQ
zilucoplan sodium
C5 1 indications · 2023

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Competitive Matchups Pro

Loading...

Recent Activity

ZILBRYSQ 2026-01-22
Labeling
AMITRIPTYLINE HYDROCHLORIDE 2026-01-09
Labeling
HYDROCODONE BITARTRATE AND ACETAMINOPHEN 2026-01-08
Labeling
HYDROCODONE BITARTRATE AND ACETAMINOPHEN 2025-12-31
Labeling
HYDROCODONE BITARTRATE AND ACETAMINOPHEN 2025-12-31
Labeling
HYDROCODONE BITARTRATE AND ACETAMINOPHEN 2025-12-31
Labeling
HYDROCODONE BITARTRATE AND ACETAMINOPHEN 2025-12-31
Labeling
HYDROCODONE BITARTRATE AND ACETAMINOPHEN 2025-12-31
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Neurology 78%
7 drugs
Immunology 22%
2 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

AbbVie big-pharma
Immunology, Neurology
GSK big-pharma
Immunology, Neurology
Eli Lilly big-pharma
Immunology, Neurology
Roche big-pharma
Neurology, Immunology
Bristol-Myers Squibb big-pharma
Immunology, Neurology